Coronavirus Disease 2019 (COVID-19)

Training slides based on guidelines for case-finding, diagnosis, management and public health response in South Africa

Compiled by

Centre for Respiratory Diseases and Meningitis and Outbreak Response, Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS)

and

National Department of Health, South Africa
Including Communicable Diseases Cluster, Zoonotic Diseases Cluster, Port Health, Environmental Health
and Emergency Medical Services

VERSION 6 2020-03-02







Outline

- Microbiology, epidemiology and clinical presentation
- Surveillance for imported cases including case definitions
- Laboratory diagnosis
- Infection prevention and control
- Patient flow and actions required at each step
- Co-ordinating a public health response



HOW TO STAY INFORMED:

THIS SITUATION IS RAPIDLY EVOLVING

Please check for updates on the NICD and NDoH websites

www.nicd.ac.za and www.ndoh.gov.za

Find the latest information from WHO on where COVID-19 is spreading:

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

Advice and guidance from WHO on COVID-19

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

https://www.epi-win.com/





Microbiology, epidemiology and clinical presentation



Microbiology and epidemiology

- Coronaviruses are enveloped, single-stranded positive-sense RNA viruses.
- The envelope of the coronaviruses is covered with club-shaped glycoproteins which look like 'crowns', or 'halos' – hence the name 'coronavirus.'
- Coronaviruses are responsible for the common cold, and usually cause self-limited upper respiratory tract infections.
 - Examples 229E, NL63, OC43 and HKU1
- Previous cross animal human barrier SARS and MERS









COVID-19: what is it and where are we at?

- 31 December 2019, the World Health Organization (WHO) China country office reported a cluster of pneumonia cases in Wuhan, Hubei Province of China
- 7 January 2020, causative pathogen identified as a novel coronavirus (Virus: SARS-CoV-2, COronaVirus Disease-2019 (COVID-19))
- Initially person-to-person transmission not apparent, majority of the cases were epidemiologically linked to a seafood, poultry and live wildlife market (Huanan Seafood Wholesale Market) in Jianghan District of Hubei Province
- Number of cases continued to increase rapidly, and evidence of person-to-person transmission mounted






Figure 3: Epidemic curve of 2019-nCoV cases (n=191) identified outside of China, by date of reporting and travel history, 5 February 2020



Division of the National Health Laboratory Service

COVID-19: what is it and where are we at?

Figure 2. Epidemic curve of confirmed COVID-19 cases (n=6567) reported outside of China, by date of report and WHO region with complete days of reporting through 29 February 2020



Transmissibility

- Main route of transmission respiratory <u>droplets</u>
 (airborne transmission has not proven)
- Excreted in stool (possibly faeco-oral)
- Mean incubation period 5.2 days (95% confidence interval [CI], 4.1 to 7.0), 95th percentile of the distribution at 12.5 days.
- 14 days of isolation or quarantine is suggested as it allows a window of 1.5 additional days. (Li, 2020)
- In early stages, epidemic doubled in size every 7.4 days
- Basic reproductive number was estimated 2.2 (95% CI, 1.4 to 3.9) on average each infectious case gives rise to just over 2 infectious cases.





Clinical presentation

Who is at highest risk?

- Largest published series to date from China 99 COVID-2019 patients with pneumonia the commonest symptoms were fever (83%), cough (82%) and shortness of breath (31%).(Chen et al Lancet 2020)
- The majority (but not all) of severe cases are elderly or have severe underlying illness
- Among pneumonia patients 51% had chronic diseases
- 11 patients who died, 7 aged >60 years, 3 had long history of smoking and 3 had hypertension

Number of cases and deaths continue to increase

- Approximately 2% of reported confirmed cases have died
- Higher case fatality in critical cases and elderly
- Likely a substantial overestimation of the true case fatality ratio:
 - More severe disease tends to be reported first
 - Initial case definition in China really focused on patients with pneumonia
 - Possible backlog in testing and confirming cases in China



Surveillance and case definitions

Clinical and epidemiological criteria for person under investigation (PUI)

Criteria for Person Under Investigation (PUI)

- Persons with acute respiratory illness with sudden onset of at least one of the following: cough, sore throat, shortness of breath or fever [≥ 38°C (measured) or history of fever (subjective)] irrespective of admission status AND
- In the 14 days prior to onset of symptoms, met at least one of the following epidemiological criteria:
- Were in close contact¹ with a confirmed² or probable³ case of SARS-CoV-2 infection;

OR

- Had a history of travel to areas with presumed <u>ongoing community transmission of SARS-CoV-2</u>;
- Worked in, or attended a health care facility where patients with SARS-CoV-2 infections were being treated.

OR

- Admitted with severe pneumonia of unknown aetiology
- 1 Close contact: A person having had face-to-face contact or was in a closed environment with a COVID-19 case; this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated. ² Confirmed case: A person with laboratory confirmation of SARS-CoV-2 infection, irrespective of clinical signs and symptoms. ³ Probable case: A PUI for whom testing for SARS-CoV-2 is inconclusive (the result of the test reported by the laboratory) or for whom testing was positive on a pan-coronavirus assay.

If testing is indicated, what next?

- Isolate the patient using appropriate infection prevention control (see next section)
- Collect a specimen ASAP (see next section)
- Identify contacts
- DOH will follow up



Who is a close contact

- A person having had face-to-face contact (within 2 metres) or was in a closed environment with a COVID-2019 case; this includes,
 - amongst others, all persons living in the same household as a COVID-2019 case and, people working closely in the same environment as a case.
 - A healthcare worker or other person providing direct care for a COVID-2019 case.
 - A contact in an aircraft sitting within two seats (in any direction) of the COVID-2019 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated.



Monitoring of close contacts and Health workers with occupational exposure

- Close contacts under monitoring should be advised to:
 - Remain at home (NICD can provide an official letter for employment or education facilities)
 - Avoid unnecessary social contact
 - Avoid travel
 - Remain reachable for monitoring
- Health Worker with occupational Exposure
 - Lists of healthcare workers with occupational exposure should be compiled by the health facility
 - They should be actively monitored for symptoms and rapidly isolated and tested should symptoms develop



Quarantine



- Quarantine means separating asymptomatic persons who are exposed to a disease from non-exposed persons
- Quarantine is to be distinguished from isolation, which is the act of separating a sick individual with a contagious disease from healthy individuals without that contagious disease
- Quarantine procedures can be effective in limiting and slowing the introduction of a novel pathogen into a population but may entail the use of considerable resources and may infringe on the rights of members of society.
- Quarantine may take place
 - in the home
 - or in a designated facility.
- Depending on level of risk, and intensity of the exposure, different levels of quarantine will be employed, for example
 - If a person is expatriated from Wuhan, quarantine at a facility will be recommended.
 - A household member of a confirmed case will be asked to stay in their home for 14 days
 - if health worker wearing appropriate PEP is exposed to a confirmed case, the health worker would be allowed to work but would be requested to self-quarantine if symptoms develop within 14 days.

Contact line List

Details of case under investigation/confirmed case

Date Symptom

Alternative number

Onset

Name



NICD Identifier

Contact number

Surname

2019-nCoV CONTACT LINE LIST

DD/MM/YYYY

health

Department:
Health
REPUBLIC OF SOUTH AFRICA

DD/MM/YYYY

Today's date

Facility name

Telephone

Name

Complete a contact line list for every case under investigation and every confirmed case

Surname

Email address

Role

Details of health official completing this form

Air/bus line	Flight/bus #				Seat #					
Details of contact	ts (With close contact	¹ 7 days p	rior to	symptom onset, oi	during sympto	matic illness.)				
Surname	First name(s)	Sex (M/F)	Age (Y)	Relation to case ²	Date of last contact with case	Place of last contact with case (Provide name and address)	Residential address (for next month)	Phone number(s), separate by semicolon	HCW?³ (Y/N) If Yes f acility name	
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					
					DD/MM/YYYY					

closely in the same environment as a case. A healthcare worker or other person providing direct care for a 2019-nCoV case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the 2019-nCoV case, travel companions or persons providing care, and crew members serving in the section of the aircraft

where the index case was seated.. ² Chose from: Aunt, Child, Class mate, Colleague, Cousin, Father, Friend, Grandfather, Grandmother, Healthcare worker taking care of, Mother, Nephew, Niece, Other relative, Uncle. ³ Healthcare worker.

Page 1 of 2

Continues on reverse

Please refer to www.nicd.ac.za for most recent version of this document before use.


Version 4, 5 February 2020

PDF version at: http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/

To be emailed to PDF version at: http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/



Contact tracing summary



^{*} Close contact: A person having had face-to-face contact (≤2 metres) or was in a closed environment with a 2019-nCoV case; this includes, amongst others, all persons living in the same household as a 2019-nCoV case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a 2019-nCoV case, while **not** wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the 2019-nCoV case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated.

** Casual contact: Anyone not meeting the definition for a close contact but with possible exposure.

NATIONAL INSTITUTE FOR

Division of the National Health Laboratory Service

COMMUNICABLE DISEASES

^{***}Monitoring methods: Active-telephonic monitoring: NICD call centre will phone person who is home-quarantined each day for a symptom report; Self-monitoring: person to consult healthcare practitioner in the event of symptom development.

Laboratory diagnostics

Who should be tested?

- Only patients under investigation (PUI) for COVID-2019 should be tested
- Please discuss plans to collect samples with doctor on call before collecting sample: NICD hotline – 082 883 9920
- Rapid collection, transport and testing of appropriate specimens from PUI is a priority
- Patients should be managed as potentially infected when the clinical and epidemiological data strongly suggest COVID-2019 infection



Specimen Collection

- Lower respiratory tract samples are preferred.
- Respiratory samples are the primary method if diagnosis.
- Respiratory samples include:
 - Combined nasopharyngeal and oropharyngeal swab (placed in the same tube)
 in ambulatory patients and
 - sputum (if produced)
 - Tracheal aspirate or Broncho alveolar lavage in patients with more severe respiratory disease.
- Serum for serological testing acute and convalescent samples may be submitted in addition to respiratory samples.
- Use universal/viral transport medium for swabs if available and if not dry swabs; sterile container for sputum and aspirates; clotted blood container for serum



Equipment and materials

- 1. Specimen submission form and case investigation form.
- 2. Nasopharyngeal (NP) and oropharyngeal (OP) flocked swab.
- 3. Tube containing universal transport medium (UTM).
- 4. Tongue depressor.
- 5. Gloves.
- 6. N95 mask (fit tested), goggles/visor (your own spectacles are not sufficient)
- 7. Biohazard bag for disposal of non-sharp materials.
- 8. Tissue for patient to wipe nose after sample collection.
- 9. Cooler box and cooled ice packs.
- 10. Ziploc plastic specimen bag.




Collection of nasopharyngeal swab (NPS)

- 1. Don a pair of gloves, and an N95 respirator, making sure the respirator has a good fit. Open a sterile flocked swab at the plastic shaft
- 2. Ask the patient to tilt his/her head back. Estimate the distance from the patient's nose to the ear: This is how far the swab should be inserted
- 3. Gently insert swab into the nostril and back (not upwards) to the nasopharynx until a slight resistance is met
- 4. Rotate swab 2-3 times and hold in place for 2-3 seconds
- 5. If resistance is met remove and try another nostril
- 6. Slowly withdraw swab and without touching it, put it into a UTM
- 7. Break plastic shaft at the break point line and close the tube



Collection of oropharyngeal swab (OPS)

- 1. Keeping the same pair of gloves on, and holding the UTM with the nasopharyngeal swab in, take a second flocked swab and open it at the plastic shaft
- 2. Ask the patient to tilt their head back and open mouth wide
- 3. Hold the tongue down with a tongue depressor
- 4. Have the patient say "aahh" to elevate the uvula
- 5. Swab each tonsil first, then the posterior pharynx in a "figure 8" movement
- 6. Avoid swabbing the soft palate and do not touch the tongue with the swab tip as this procedure can induce the gag reflex.
- 7. Place the swab into the same UTM tube with the NPS already in and break off the shaft at the break point line
- 8. Tightly close the tube
- 9. Place the closed tube with two swabs in the Ziploc
- 10. Remove PPE in correct sequence
- 11. Wash hands with soap and water





Swabs Important Information

- Clearly mark each specimen (e.g. Left Nasal Swab Tight Nasal Swab)
- If you send multiple swabs unmarked the lab has no idea where they come from
- You must identify which facility the swab comes from
- Clinicians name and contact details are important



Hand hygiene before and after any interaction with the patient





Transport of specimens

- 1. Ensure the cooler box and ice packs stay at 2-8 degrees Centigrade.
- 2. Transport to CRDM, NICD on same day as collection.
- 3. Mark: Suspected Novel coronavirus, CRDM NHLS/NICD, Centre for Respiratory
 Disease and Meningitis (CRDM) Lower North Wing, SAVP building 1 Modderfontein
 Rd, Sandringham, Johannesburg, 2131.
- 4. NHLS laboratories use usual overnight regional courier service.
- 5. Private laboratories/clinics to organise shipment using existing systems, or contact CRDM for assistance if not available.



Step 1: Report the PUI

- Report the PUI to the NICD to allow a risk assessment to be carried out and guide laboratory testing
- 2. Contact the NICD Hotline +27 82 883 9920
- 3. The test will be free of charge for patients meeting the case definitions above



Record keeping

• 1. Complete the specimen submission form and case investigation form (available on NICD website). http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/

- 2. Place the specimen submission form into a ziplock bag.
- 3. Label the tube of universal transport media (UTM) with the patient's name and date of birth.



Complete the correct forms

- For each person under investigation (PUI) a laboratory specimen submission form and a person under investigation (PUI) form has to be completed and submitted together with the specimens
- Always check on the NICD website that you have the current version of the forms http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/

		CRDM lab	no:		Trak no:			Date rece	eived:		
A NATIONAL INSTIT			Cent	re for R	Respiratory	/ Diseases ar	nd Menir	ngitis			
COMMUNICABLE Obvious to the National People La			Specimen Submission form								
Patient Informatio	<u>n</u>			5	ubmitter Ir	nformation (contact p	erson for	results)		
ldentifier or Hospit	tal no			3	Surname						
Surname					First name					_	
First name					Laboratory						
Age/Date of birth				(City, Countr	у					
Gender				(Contact nur	mber (country cod	+()			
Facility/Hospital					Email addre	255					
Specimen Details											
pecimen collectio	n date:		dd-mm-y	ryyy							
Specimen type:		Con	nbined NP/OP sv	vab	☐ Nas	opharyngeal	(NP) aspi	irate	□ N	asal swa	
оресппен турет		☐ Nas	opharyngeal (NF) swab	☐ Bro	nchoalveolar	lavage (E	BAL)	□ Sp	outum	
		Ord	pharyngeal (OP)	swab	_ Pleu	ıral fluid				SF	
		Tra	cheal aspirate (T	A)	Bloc	od culture			□ Se	erum	
		— □ Wh	☐ Whole blood			Other, specify:			□		
Laboratory Test De	etails (ple	ase consult wit	h CRDM if testing o	other tha	an influenza	RSV or B. pert	ussis is re	quired)			
Refer to page 2 for		ohtheriae n A strentoco			panel (bacte	Atypical Atypical erial & viral)*	_	☐ Vii	ral menii her sne		
test panel details	Grou	p A streptocoo p B streptocoo	ccus Comr	ratory p nunity-	panel (bacto acquired pr uired pneu	erial & viral) neumonia (ba monia (bacte	cteria) ria)	Uii Ot	her, spe		
test panel details Clinical Presentation	Grou	p A streptocoo p B streptocoo utcome	ccus Comr	iratory i munity- ital-acq	panel (bacte acquired pr uired pneu Date of sy	erial & viral)* neumonia (ba monia (bacte ymptom onse	ria)*	□ Vii □ Ot	her, spe		
test panel details	Grou	p A streptocoo p B streptocoo utcome e rheumatic fe theria	ccus Comr	iratory p munity- ital-acq ingococ enza-lik	panel (bacter acquired pr uired pneur Date of sy cal disease e illness	erial & viral) neumonia (ba monia (bacte	ria)* et: espiratory	dd-mm / tract infe	ther, spe		
test panel details Clinical Presentation	Group Group On and O Acute Diphe	p A streptocoo p B streptocoo utcome e rheumatic fe theria	ccus Comr	iratory p munity- ital-acq ingococ enza-lik ingitis	panel (bacte acquired pr uired pneul Date of sy cal disease e illness	erial & viral)* neumonia (bacte monia (bacte mptom onse Lower re	ecteria)* ria)* et: espiratory pecify:	dd-mm / tract infe	ther, spe		
test panel details Clinical Presentation Clinical diagnosis:	Group Group On and O Acute Diphe Pertu	p A streptocoo p B streptocoo utcome e rheumatic fe theria ussis	ever Meni	iratory promity- ital-acq ingococ enza-lik ingitis	Date of sy cal disease e illness	erial & viral)* neumonia (bacte monia (bacte mptom onse Lower re Upper re	ecteria)* ria)* et: espiratory pecify: e	dd-mm / tract infe	ction ction ction	ecify:	
test panel details Clinical Presentation Clinical diagnosis:	Group Group On and O Acute Diphe Pertu Fever	p A streptocomp B streptocomoutcome e rheumatic featheria ussis r (≥38°C) tness of breatl	ever	iratory promity-iral-acq	Date of sy cal disease e illness	erial & viral)* neumonia (bacte monia (bacte mptom onse Lower re Upper re Other, sp	et: espiratory ecify: e	dd-mm / tract infe	ction ction iff neck	ecify:	
test panel details Clinical Presentation Clinical diagnosis:	Group On and O Acute Diphe Pertu Fever Short Apno	p A streptocoop p B streptocoo utcome e rheumatic fe theria ussis r (≥38°C) tness of breatl ea □ Otho	ever	iratory promity-iratory promit	Date of sycal disease e illness Cough Diarrhoea	erial & viral)* neumonia (bacte monia (bacte) monia (bact	et: espiratory ecify: e	dd-mm / tract infe / tract infe	ction ction iff neck ry whoo	pp □ TB	
Clinical Presentation Clinical diagnosis: Symptoms: Juderlying Risk Fac	Group On and O Acute Diphe Pertu Fever Short Apno	p A streptocoop p B streptocoo utcome e rheumatic fe theria ussis r (≥38°C) tness of breatl ea □ Otho Asthma Heart Disea	ccus Comr ccus Hospi ever Meni Influe Meni Sore Thro n Vomiting er, specify: Chronic Lun	iratory promity-iratory promity-iratory promity-iratory promity promit	Date of sycal disease e illness Cough Diarrhoea	erial & viral)* neumonia (bacte monia (bacte) monia (bact	et: espiratory espiratory ecify: e nal cough	dd-mm / tract infe / tract infe / tract infe / Sti	ction ction iff neck ry whoo	pp □ TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factoria	Group On and O On and	p A streptocomp B streptocomp utcome e rheumatic featheria ussis r (≥38°C) tness of breatheria Disea Heart Disea ttient ent— not adm	ccus	iratory promity-iratory promity-iratory promity-iratory promity promit	Date of sycal disease e illness Cough Diarrhoea	erial & viral)* neumonia (bacte monia (bacte)	et: espiratory espiratory ecify: e nal cough	dd-mm / tract infe / tract infe / tract infe / Sti	ction ction iff neck ry whoo	pp □ TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factorial	Group On and O On and	p A streptocomp B streptocomoutcome e rheumatic featheria ussis r (≥38°C) tness of breatles a Other Asthma Heart Disea stient ent—not adment—admitte	ccus	iratory promity-iratory promity-iratory promity-iratory promity promit	Date of system of the control of the	erial & viral)* neumonia (bacte monia (bacte) monia (bac	et: espiratory espiratory ecify: e nal cough	dd-mm / tract infe / tract infe / tract infe / Sti	ction ction iff neck ry whoo	pp	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factorial	Group Group On and O Acute Diphe Pertu Fever Short Apno ctors: Inpatie	p A streptocomp B streptocomoutcome e rheumatic featheria ussis r (≥38°C) tness of breatles a Other Asthma Heart Disea stient ent—not adment—admitte	ccus	iratory promity-iratory promity-iratory promity-iratory promity promit	Date of system of the control of the	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory ecify: e nal cough	dd-mm / tract infe / tract infe / tract infe / Sti	ction ction iff neck ry whoo	pp □ TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factorial	Group On and O Acute Diphe Pertu Short Short Inpatie Unkno	p A streptocomp B streptocomoutcome e rheumatic featheria ussis r (≥38°C) tness of breatles Asthma Heart Disea trient ent—not admitte own	ccus	iratory promity-iratory promit	Date of system of the control of the	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / tract infe / tract infe / Sti	ction ction iff neck ry whoo	pp □ TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Exposure History	Group Group Group Group Group Acute Diphe Pertu Fever Short Apno ctors: Unknown	p A streptocomp B streptocomp	cus Comr cus Hospi ever Meni Influe Meni Sore Thro Nomiting er, specify: Chronic Lun se Other, sp	iratory promity-iratory promit	Date of system of the control of the	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / tract infe / tract infe / Pregna	ction ction iff neck ry whoo	p TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Hospitalisation: Exposure History Did the patient tra	Group Group Group Group Group Acute Diphe Pertu Fever Short Apno ctors: Unknown	p A streptocomp B streptocomp	ccus Comr ccus Hospi ever Meni Influe Meni Sore Thro Nomiting er, specify: Chronic Lung se Other, sp iitted ICU d to ICU Date of	iratory promity-iratory promit	panel (bacteracquired property	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / tract infe / tract infe / Pregna Unknown	ction ction iff neck ry whoo one ancy	p TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Hospitalisation: Exposure History Did the patient tra	Group Group Group Group Group Acute Diphe Pertu Fever Short Apno ctors: Unknown	p A streptocomp B streptocomp	ccus Comr ccus Hospi ever Meni Influe Meni Sore Thro Nomiting er, specify: Chronic Lung se Other, sp iitted ICU d to ICU Date of	iratory promity-iratory promit	panel (bacteracquired property	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm y tract infe y tract infe y tract infe Dhinspirato No	ction ction iff neck ry whoo one ancy	p TB	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Hospitalisation: Exposure History Did the patient tra Area/Count 1.	Group On and O Acute Diphe Pertu Short Apno ctors: Unkno	p A streptocomp B streptocomp	ccus Comr ccus Hospi ever Meni Influe Meni Sore Thro n Vomiting er, specify: Chronic Lung se Other, sp nitted ICU d to ICU r to symptom on Date of	iratory promity-iratory promit	panel (bacter acquired property propert	erial & viral)* neumonia (bacte monia monia (bacte monia mo	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / Unknown of travel fo	ction ction iff neck ry whoo one ancy	pp TB Nor	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Hospitalisation: Exposure History Did the patient tra Area/Count	Group On and O Acute Diphe Pertu Short Apno ctors: Unknot uny travelle ve anima	p A streptocomp B streptocomp	ccus Comr ccus Hospi ever Meni Influe Meni Sore Thro n Vomiting er, specify: Chronic Lung se Other, sp nitted ICU d to ICU r to symptom on Date of	iratory promity-iratory promit	Date of syncal disease e illness Cough Diarrhoea se Di ome:	erial & viral)* neumonia (bacte monia monia (bacte monia mo	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / Unknown of travel for dd-mm-	ction ction iff neck ry whoo one ancy own	pp TB Nor	
Clinical Presentation Clinical diagnosis: Symptoms: Underlying Risk Factory Hospitalisation: Exposure History Did the patient tra Area/Count 1.	Group Group Group Acute Diphe Pertu Fever Short Apno ctors: Inpatie Unknown avel in the cry travelle ve anima	p A streptocomp B streptocomp	cus Comr cus Hospi ever Meni Influe Meni Sore Thro Nomiting er, specify: Chronic Lun se Other, sp nitted ICU d to ICU r to symptom or Date of	iratory in munity-ital-acq ingococenza-lik ingitis pat pecify:Outcome to symp	Date of sylvate of syl	erial & viral)* neumonia (bacte monia (bacte	et: espiratory espiratory ecify: e nal cough HIV alised	dd-mm / tract infe / Unknown of travel for dd-mm-	ction ction iff neck ry whoo one ancy om this a	pp TB Nor	

CRDM episode no: CRDM la	ab no: Trak no:	Date received:
--------------------------	-----------------	----------------

CRDM PCR Diagnostic Test Panels:

Test name:	Pathogens:				
Respiratory panel	Viruses:				
	Influenza A, influenza B, influenza C, rhinovirus, human coronavirus, parainfluenza				
	virus, human bocavirus, human metapneumovirus, enterovirus, adenovirus,				
	parechovirus, respiratory syncytial virus (RSV)				
	Bacteria:				
	Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae,				
	Haemophilus influenzae type B, Staphylococcus aureus, Klebsiella pneumoniae,				
	Legionella spp., Salmonella, Bordetella pertussis, Moraxella catarrhalis				
	Fungi:				
	Pneumocystis jiroveci				
Community-acquired pneumonia	Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae,				
	Moraxella catarrhalis				
Hospital-acquired pneumonia	Klebsiella pneumoniae, Pseudomonas aeruginosa				
Atypical pneumonia	Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp.				
Neonatal sepsis	Group B streptococcus, Listeria monocytogenes, Staphylococcus aureus,				
	Chlamydia trachomatics, Ureaplasma urealyticum/parvum, cytomegalovirus				
Bacterial meningitis	Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae				
Viral meningitis	Adenovirus, cytomegalovirus, epstein barr virus, herpes simplex virus 1, herpes sim-				
	plex virus 2, varicella zoster virus, enterovirus, parechovirus, human herpesvirus 6,				
	human herpesvirus 7, parvovirus B19, mumps virus				



Person under investigation form (CIF)





Final version 2_31JANUARY 2020

	L INSTITUT IICABLE DI	THE RESERVE OF THE PARTY OF THE		Department:	OUT	BREAK RESPONSE, DIVIS	ION OF PUBLIC			
Division in the Natio		ACCUSED AND ADDRESS OF THE PARTY OF THE PART		Health REPUBLIC OF SOUTH AF	RICA		38	AND RESPO	INSE	
						Interna				
Patient under i	investigat	ion (PUI) fo	orm: Re	equest for 2019-nCo	oV Testing					
	Dlease note	that the orig	inal case	investigation forms sh	ould be sent	together with the speci	imen collection	form		
Furt	hermore, th	ne completed	case inv	estigation form must be	e scanned ar	nd emailed to ncov@nice 883 9920 Queries / sub	d. ac.za as detai	led below		
oday's DD/I	MM/YYYY	Form comp	leted by	(Name, Surname):	Contact number(s):					
this a: New	clinical que	ery 🗆		act of a known case,	Known case first name:					
Cont	act of a kno	own case \square	provid	e case details:	Known ca	se surname:				
					Known ca	se DOB:	DD/MN	1/YYYY		
etected at point of	of entry?	Y□ N□ Unk	:n□	If yes, date: DD/MM/	YYYY	Please specify the	oint of entry:			
		PATIEN	IT DETAI	LS			DOCTOR'S DE	TAILS		
atient hospital nu	mber (if av	ailable):	_	AVERAGE AND		First name:				
rst name:			Surnam	e:		Surname:				
OB: DD/I	MM/YYYY		Sex:	Male Female		Facility name:				
esidency: SA re	esident 🗆	Non-SA reside	ent 🗆 (s	pecify)		Contact				
urrent residentia	Address1:					number/s:				
atient's contact n ease include alternativ						Email address:				
		Student		Unemployed						
lease indicate occ	upation	Working with		Health laborato worker	ory					
ick any if apply):		animals Healthcare		worker						
		worker		Facility name:_						
		Other		Specify						
			NEXT (OF KIN CONTACT DETAIL	LS (alternativ	e contact details)				
rst name:				s	Surname:					
elationship to the	patient:				Contact numb	per(s):			_	
				CLINICAL PRESENTA	TION AND H	ISTORY				
ate of symptom	DD/	/MM/YYYY		Date of o	current cons	ultation/admission:	D/MM/YYYY			
iiset.	Fever	(≥38°C		Sore throat		Myalgia/body pains				
ymptoms (tick all	Histor	History of fever		Shortness of breat	th 🗆	General weakness				
nat apply):	Cough	ļ		Nausea/vomiting		Irritability/confusion				
	Chills			Diarrhoea		Other		(specify if other)		
				DIAG	NOSIS					
Did the patient h	ave clinical	or radiologica	ıl evide n	ce of pneumonia	Y N					
Were chest X-ray	s (CXR) don	ne:			Y N	If yes, CXR Findings:	3/58/- A 1/59/- A 1/59/- A		2000	
Did the patient have clinical or radiological evidence of acute respiratory distress syndrome (ARDS)?					Y□ N□					
Does the patient illness?	have anoth	er diagnosis/e	etiology	for their respiratory	Y□ (specif	y)	N□	Unknown□		




Contact details for additional assistance

- Sample collection
 - Sibongile Walaza sibongilew@nicd.ac.za 011-386-6410
- Sample transport
 - Linda de Gouveia lindad@nicd.ac.za 011-555-0327
 - Amelia Buys ameliab@nicd.ac.za 011-386-6373
 - Cardia Fourie cardiaf@nicd.ac.za 011-386-6373
- http://www.nicd.ac.za/wp-content/uploads/2020/02/2019-nCov-Quick-reference-v3-03.02.2020-final.pdf



Laboratory diagnostic assays



- Real-time reverse-transcription polymerase chain reaction (rRT-PCR) - amplification and detection of unique COVID-2019 viral nucleic acid sequences
- TAT 24 hours
- Positive specimens characterised by viral culture and whole genome sequencing

Eurosurveillance Jan 2020

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Victor M Corman¹, Olfert Landt², Marco Kaiser², Richard Molenkamp³, Adam Meijer⁴, Daniel KW Chu⁵, Tobias Bleicker¹, Sebastian Brünink¹, Julia Schneider¹, Marie Luisa Schmidt¹, Daphne GJC Mulders³, Bart L Haagmans³, Bas van der Veer⁴, Sharon van den Brink⁴, Lisa Wijsman⁴, Gabriel Goderski⁴, Jean-Louis Romette⁶, Joanna Ellis७, Maria Zambon७, Malik Peiris⁵, Herman Goossens⁶, Chantal Reusken⁴, Marion PG Koopmans³, Christian Drosten¹




Interpretation of rRT-PCR results

- Negative result does not rule out possibility of infection
- Factors that could lead to a false –negative result:
 - Poor specimen quality
 - Specimen was collected late or very early in the illness
 - Specimen was not handled and shipped appropriately, (eg. the cold chain)
 - Technical reasons inherent in the test, e.g virus mutation

If negative results are obtained from patients with a high index of suspicion for COVID-2019 infection, especially when only upper respiratory tract samples were collected, additional specimens, including lower respiratory samples should be collected and tested.



Infection prevention and control



Direct contact

- Touching an ill persons or a contaminated surface
- E.g. agents of diarrhoea, skin infections, common cold, ebola virus

Control

Gloves, +/- gowns, masks, visors (to prevent mucous membrane splashes, contamination of clothing)

Droplet transmission

- Inhaling droplets (up to 1/4mm in diameter)
 Persons within 2m radius are at
- risk. On aircraft, 2 rows behind and in front
- E.g. agents of bacterial pneumonia, Neisseria meningitides

Control

Gloves, surgical masks, +/- gowns, masks, visors (to prevent mucous membrane splashes, contamination of clothing)

Airborne transmission

- Inhaling droplets nurclei (<5um in diameter)
- Persons breathing the same air
- E.g. influenza, measles, chickenpox,

Control

Gloves, N95 masks, +/- gowns, masks, visors (to prevent mucous membrane splashes, contamination of clothing)



Vector transmission

- Contact with vector
- E.g. malaria, dengue, Zika,


Control

- Prevent/eliminate
- exposure to vector Chemoprophylaxis if possible




Principles of infection prevention and control (IPC)

A safe environment can be achieved through elimination of infectious particles in the air and on surfaces




Decrease the number of particles formed by people with COVID

Administrative controls



Remove the particles from the air and from surfaces

Environmental controls



Prevent people from inhaling the particles or touching their mucous membranes with contaminated hands

Personal protective equipment and risk reduction

IPC strategies to address suspected COVID infection

- Ensure triage, early recognition and source control (early isolation of persons with suspected COVID infection)
- Apply standard precautions for all patients
- Implement empiric additional precautions for suspected cases (droplet, contact and airborne where applicable)

- Implement administrative controls (IPC committee, checklist, assign responsibility for opening windows and triaging)
- Use environmental controls (open windows, UV light, ensure airflow direction protects HCW)
- Use engineering controls (ensure air circulation is functional with appropriate number of air changes per hour)



In all facilities....

- Implement screening for COUGH, respiratory symptoms and TRAVEL HISTORY at entrance to the facility / clinic / casualty / hospital
- Put a sign up asking for persons with a travel history to China in last 14 days to identify themselves to staff
- Provide surgical masks to persons who sneeze, cough etc
- See persons who have symptoms first
- Encourage hand hygiene amongst patients and HCW



In all facilities.....

- Ensure hand hygiene for HCW and patients is possible, and done!
- Provide soap, basins
- Use posters to show 5movements of hand hygiene
- Provide hand sanitiser
- Use health promotion staff to demonstrate hand and cough hygiene



Rotational rubbing of left thumb

clasped in right palm and vice versa.

Backs of fingers to opposing palms with

fingers interlocked.



Once dry, your hands are safe.

When caring for someone with suspected COVID-19

Implement contact and droplet precautions

- Put in a well ventilated isolation room
 - Ensure air-conditioning system is well maintained
- Provide patient with a mask
- Implement contact and droplet precautions
- Limit the number of staff who can enter the isolation room
- Limit patient movement use portable X-rays.

Implement contact and droplet precautions


- Surgical/medical mask
- Disposable gown
- Gloves
- Eye protection

Not required for droplet precautions

- Boots, apron not required
- Negative pressure respiratory isolation room not required.

When caring for someone with suspected COVID-19

- When taking a sputum specimen or nasopharyngeal swab use <u>airborne</u> and contact precautions are required
 - E.g. nasopharyngeal swabs, intubation, tracheal aspirate, suction etc
- When nursing a ventilated patient in ICU
 - Use N95 respirator to ensure a tight seal
- Always use gown, gloves
- Use a face-shield or goggles
- Boots or shoe covers are not required



Rational use of personal protective equipment for coronavirus disease (COVID-19)

Interim guidance 27 February 2020

COVID-19 virus, was first detected in Wuhan city, China in disease (COVID-19), December 2019. On 30 January 2020, the WHO Director General declared that the current outbreak constituted a Public Health Emergency of International Concern.

rational use of personal protective equipment (PPE), includes gloves, medical masks, goggles/face shield, gowns, as well as respirators (e.g. N95 or FFP2) and aprons for specific procedures, in health care and community settings, including the handling of cargo. This document is intended for those involved in the distribution and management of PPE, as well as public health authorities and individuals in health care and community settings to understand when PPE use is

WHO will continue to update these recommendations as new

Preventive measures for COVID-19

Based on currently available evidence, the COVID-19 virus is transmitted between people through close contact and droplets; not airborne transmission. People most at risk of infection are those who are in close contact with a COVID-19

PPE is only one effective measure within a package that comprises of administrative and environmental/engineering controls as described in the WHO Infection Prevention and ontrol (IPC) for epidemic and pandemic-prone acute respiratory infections (Infection prevention and control during epidemic- and pandemic-prone respiratory infection

1. Administrative controls: ensure availability of resources for IPC, including infrastructure, clear IPC policies, facilitated access to laboratory testing, appropriate triage and placement of the patients, and adequate staff-to-patient ratios and training.


Environmental and engineering controls: these measures aim at reducing the spread of the pathogens and to reduce the contamination of surface and inanimate objects. This includes the provision of adequate space to allow social distance (at least 1 meter) between patients and between patients and health care workers, and availability of well-ventilated isolation rooms for suspect or confirmed COVID-19 patients.

COVID-19 is a respiratory disease which is different from Ebola Virus Disease (EVD), that is transmitted through infected bodily fluids. Due to these differences in transmission, the PPE requirements for COVID-19 are different to those for EVD. Specifically, coveralls (sometimes called 'Ebola PPE') are not required when managing

Training in use of IPC

Ensure staff are trained and familiar with

- Triage
- Handwashing
- Screening
- Case definitions
- Use of PPE





Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected

Interim guidance 25 January 2020



WHO/2019-nCoV/IPC/v2020.2

Introduction

This is the first edition of guidance on infection prevention and control (IPC) strategies for use when infection with a novel coronavirus (2019-nCoV) is suspected. It has been adapted from WHO's Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, based on current knowledge of the situation in China and other countries where cases were identified and experiences with severe acute respiratory syndrome (SARS)-CoV and MERS-CoV.

WHO will update these recommendations as new information becomes available.

This guidance is intended for healthcare workers (HCWs), healthcare managers and IPC teams at the facility level but it is also relevant for the national and district/provincial level. Full guidelines are available from WHO.²

Principles of IPC strategies associated with health care for suspected nCoV infection

To achieve the highest level of effectiveness in the response to an 2019-nCoV outbreak using the strategies and practices recommended in this document, an IPC programme with a dedicated and trained team or at least an IPC focal point should be in place and supported by the national and facility senior management.³ In countries where IPC is limited or inexistent, it is critical to start by ensuring that at least

1. Ensuring triage, early recognition, and source control

Clinical triage includes a system for assessing all patients at admission allowing early recognition of possible 2019-nCoV infection and immediate isolation of patients with suspected nCoV infection in an area separate from other patients (source control). To facilitate the early identification of cases of suspected nCoV infection, healthcare facilities should:

- encourage HCWs to have a high level of clinical suspicion;
- establish a well-equipped triage station at the entrance of health care facility, supported by trained staff;
- institute the use of screening questionnaires according to the updated case definition (https://www.who.int/publications-detail/globalsurveillance-for-human-infection-with-novelcoronavirus-(2019-ncov) and
- post signs in public areas reminding symptomatic patients to alert HCWs.

The promotion of hand hygiene and respiratory hygiene are essential preventive measures.

2. Applying standard precautions for all patients

Standard precautions include hand and respiratory hygiene, the use of appropriate personal protective equipment (PPE) according to risk assessment, injection safety practices, safe waste management, proper linens, environmental cleaning and sterilization of natient-care equipment • If in doubt, refer to this WHO guideline

 It is ESSENTIAL to distribute this guideline to your facility staff and follow up on implementation



How can I know if my facility is ready?

- Use our facility readiness
 checklist
- Call your facility
 IPC committee
- Talk through the checklist
- Talk through a 'desktop simulation scenario'

	Novel Coronavirus (nCoV) Readiness Ch	ecklist	
		Total inFacilty	
	Number of HCW employed / working at your facility		
	Number of designated points of entry for ill patients		
	Do you have isolation units in the Facilty if yes how many beds		
	Private wards		
General information	Private ward airborn precautions(-ve Pressure cubicles)		
	Large cohort area identified Number of beds		
	Isolation area in emergency department identified		
	ICU Isolation cubicles number		
	ICU isolation cubicles -ve pressure		
Intervention area	Indicators	Values	Yes/No
Coordination	Is there a Facilty preparedness and response plan for events caused by respiratory pathogens?		No
	Do you have a committee established in the Facilty to ensure all plans are in place		No
	Do you maintain minutes of the meetings of this committee		No
	Do you have and have you reviewed plans for implementation of surge capacity procedures		No
	and crisis standards of care. Do you believe you have everything in place to identify and isolate patients with 2019-nCoV		
	and inform key facility staff and public health authorities		No
	Do you have supplies of PPE for staff in front line areas Do you have supplies of PPE for staff in Facility care areas in case of a positive or suspected		No No
	Do you have contingency plans if the demand for PPE or other supplies exceeds supply.		No No
	Have you designated an area for the isolation of patients who may be at risk for Corona virus		No
	Have polans been made to ensure that stock is accessable in the Facility		No
	Do you have a screening tool in place in all areas of entry for the Facilty		No
	Has Training on n- Cov been commenced in your Facility?		No



Patient and PUI* flow and actions required at each step

*PUI=person under investigation

Process Flow for detection and response to cases

1.1 Appendix 1 – process flow for detection and response to cases

DETECTION AND REPORTING OF SUSPECTED 2019-nCoV CASE

- The case definition must be strictly adhered to
- For any suspected case, isolate the patient in a suitable room/ unit for assessment, apply IPC measures, contact NICD Hotline to confirm if case definition is met and if sample collection is warranted.
- If so, collect specimen and complete accompanying documentation (Appendix 7).
- Guidelines for the collection and submission of specimens to NICD available on NICD website:
 http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/
 (see quick reference for healthcare workers) or appendix 5 and 6
- The facility IPC focal point, clinician or designated port health officer should complete the case investigation form and contact line list (Appendix 8, 9), forward the forms to the Provincial Communicable Disease Control and ncov@nicd.ac.za.
- All suspected cases who meet the case definition should be notified as Class 1 notifiable medical condition under "Respiratory Disease caused by a novel respiratory pathogen"

Contacts and details:

Consultant on call for Infectious Diseases

According to site-specific protocol

NICD Hotline 082-883-9920

National Health
Operations Centre
012-395-9636/37

MEDICAL MANAGEMENT

• For all cases irrespective of symptom severity, isolate the patient and apply infection precautions in accordance with site-specific standard operating procedures for this purpose. When the number of confirmed cases becomes too high, mild cases may be managed at home (self-isolation)


Contacts and details: see Appendix 14

National and Provincial CDC

Provincial Port Health

EMS

Process Flow for detection and response to cases



TRANSPORT AND/OR REFERAL OF SUSPECTED nCoV-2019 CASE TO HOSPITAL

- If facility is able to provide required clinical care for patient in isolation, referral or transfer is not indicated. If facility cannot offer required care, transfer or referral should be discussed by calling NICD Hotline.
- Transfer of patients from port of entry to healthcare facilities to be discussed with NICD Hotline, EMS will facilitate the transport arrangements.

Laboratory testing excludes 2019-nCoV

Laboratory testing confirms 2019-nCoV


- Finalize reporting and do gap analysis for responses to the case.
- Perform mitigation of any shortcomings identified during case management

MULTI-DISCIPLINARY PUBLIC HEALTH RESPONSE

- NICD report back case was confirmed to healthcare facility, clinician, patient, provincial CDC
- Provincial CDC/designated NICD personnel to perform contact tracing as described in appendix 3
- Collate information and share reports with key stakeholders.
- Handling of mortal remains of a confirmed or suspected case must be in accordance with guidelines
- Efficient and transparent communication with the media (press release/briefs)
 must be provided
- Writing of reports e.g. daily updates, preliminary and final (Appendix 13)

Initial diagnosis and management of suspected case (PUI), including infection control measures

2019 novel coronavirus (2019-nCoV) process flow for use in healthcare facilities





^{*} Close contact: A person having had face-to-face contact (\leq 2 metres) or was in a closed environment with a 2019-nCoV case; this includes, amongst others, all persons living in the same household as a 2019-nCoV case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a 2019-nCoV case, while **not** wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the 2019-nCoV case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated.

** Casual contact: Anyone not meeting the definition for a close contact but with possible exposure.

Initial diagnosis and management of suspected case (PUI), including infection control measures

2019 novel coronavirus (2019-nCoV) process flow for use in healthcare facilities





STAGE OF ASSESSMENT OF TRAVELLERS/PERSONS UNDER INVESTIGATION FOLLOWING ARRIVAL AT PORT										
Symptom status	Arrival and disembarkati on	Screening by Port Health	Screening by Port Health	Seen at Immigration and customs	In depth assessment at Port Health	Meets case definition, awaiting transfer by EMS	Transported by EMS to health facility	In Emergency Medicine Department (casualty)	Admission pending COVID result	Confirmed positive test
Unknown	X			X						
No symptoms, does not meet case definition		X		X						
Thermoscan positive			X		X					
Meets case definition					X	X	X	X	X	X

ACTIONS REQUIRED BY HEALTH CARE WORKERS REGARDING IPC, reporting and data collection AT THIS STAGE

Level of IPC care required by personnel	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions*, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab
Actions required	None	None	Immediately Port Health official gives patient a mask and moves traveller to private room,	None	Call NICD, collect throat swab, send to NICD Arrange transfer to medical facility	Limit staff entry to isolation room	Call ahead and request facility to prepare isolation room for clinical assessment	Take patient straight to isolation room Notify patient as suspected COVID	Adhere to facility IPC protocols for respiratory isolation	Adhere to facility IPC protocols for respiratory isolation
References	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	RSA Coronavirus guidelines on NICD website WHO 'IPC for NCoV'	#If possible, facilities should use airborne precautions				

	STAGE OF ASSESSMENT OF TRAVELLERS/PERSONS UNDER INVESTIGATION FOLLOWING ARRIVAL AT HEALTH FACILITY									
Symptom status	Arrival and registration	Screening by triage nurse	Screening by triage nurse	In depth assessment by Emergency Doctor	Admission pending COVID result	Confirmed positive test				
Unknown	X									
No symptoms, does not meet case definition		X								
Meets case definition			X	X	X	X				
ACTIONS REQUIRED BY HEAITH CARE WORKERS REGARDING IPC reporting and data collection ΔT THIS STAGE										

ACTIONS REQUIRED BY HEALTH CARE WORKERS REGARDING IPC, reporting and data collection AT THIS STAGE

Level of IPC care required by personnel	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Avoid crowds, keep 1m from people, frequent hand hygiene, MASKS not required*	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions*, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab	Droplet precautions*, incl surgical masks, gloves, disposable gowns, eye visor/goggles if collecting throat swab
Actions required	Screen for travel history and main complaint	Repeat screen for travel history and main complaint	Immediately provide patient with mask, and isolate patient	Collect throat swab, send to NICD	Adhere to facility IPC protocols for respiratory isolation	Adhere to facility IPC protocols for respiratory isolation; consider moving patient to designated facility
References	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	WHO guidelines 'Advice on use of masks' (*individual may choose to wear mask)	RSA Coronavirus guidelines on NICD website WHO 'IPC for NCoV'	RSA Coronavirus guidelines on NICD website WHO 'IPC for NCoV' (*airborne precautions if possible)	RSA Coronavirus guidelines on NICD website WHO 'IPC for NCoV' (*airborne precautions if possible)	RSA Coronavirus guidelines on NICD website WHO 'IPC for NCoV' (*airborne precautions if possible)

Actions following confirmation of diagnosis

- Implement appropriate precautions
 - Contact and droplet for ward-based patients
 - Contact and airborne for aerosol generating procedures
- Inform hospital manager and IPC focal point
- Notify the case on the NMC system and inform the provincial CDC co-ordinator
- Collaborate with IPC focal point, and CDC co-ordinator to collate a list of contacts
- Complete Case Report Form DAILY
- Take respiratory specimen every 2-3 days and a day before anticipated discharge to monitor for presence of virus



Clinical management

*prepared by Dr Jeremy Nel, Helen Joseph Hospital

Clinical management of suspected /confirmed COVID case is essentially management of a Severe Acute Respiratory Illness (SARI)

There are two issues:





KEEP A BROAD DIFFERENTIAL DIAGNOSIS
BEFORE DIAGNOSIS CONFIRMED

SUPPORTIVE CARE OF A SEVERE ACUTE RESPIRATORY ILLNESS



Important differential diagnosis

- Conventional bacterial pneumonia
- Atypical bacterial pneumonia
- Other viral pneumonias
- Pneumocystis pneumonia



Bacterial pneumonia

- Severe pneumonias generally require broad-spectrum antibiotics empirically.
- Recommended options for community-acquired pneumonia:

Amoxicillin-clavulanate (Augmentin)
OR

2nd or 3rd generation cephalosporin (e.g. ceftriaxone)

PLUS

macrolide (e.g. azithromycin)

2017 SA Community-acquired Pneumonia Guidelines *J Thorac Dis*. 2017;9(6):1469–1502. doi:10.21037/jtd.2017.05.31



Corticosteroids

- Avoid routine administration
- Although corticosteroids may be of benefit in severe bacterial pneumonias, they have been associated with prolonged viral shedding and increased mortality in influenza. (PMID: 30798570)
- Concern about possible similar effects in other viral pneumonias (including possibly COVID-2019)
- Should only be used if, after careful consideration, risks outweigh benefits
 - E.g. Suspected adrenal insufficiency, COPD, *Pneumocystis* pneumonia



Atypical bacterial pneumonias

- Important differential diagnosis of a viral pneumonia. Like a viral pneumonia these may have:
 - Flu-like symptoms: pharyngitis, headache, myalgias, dry cough, rhinorrhoea
 - Bilateral infiltrates can appear reticulonodular / patchy don't have to have consolidation
- Empiric treatment options:
 - Macrolide (e.g. azithromycin) OR
 - Quinolone (e.g. levofloxacin, moxifloxacin) OR
 - Doxycyline



Viral pneumonia

• Influenza, parainfluenza, human metapneumovirus, respiratory syncytial virus, adenovirus, etc.

- Influenza is an important differential diagnosis to entertain, since:
 - It is currently influenza season in the Northern hemisphere, where many of the COVID-2019 suspects will have come from.
 - It is potentially treatable.



Influenza treatment

- Consider empiric **oseltamivir** (Tamiflu) or zanamivir treatment in patients with an influenza-like illness who:
 - Are severely ill
 - Are at high risk for complications (pregnant women, HIV patients, patients with asthma/COPD, etc.)
- Treatment should be started as soon as possible (best chance of benefit within 48 hours of symptom onset)

Oseltamivir 75mg po 12-hourly for 5 days

2019clean.pdf

Pneumocystis pneumonia

Consider if:

- 1. Patient significantly immunocompromised: HIV positive with CD4 < 200, chronic systemic steroid use, chemotherapy, transplant patients, etc.)
- 2. Diffuse bilateral infiltrates (often with a mid- to lower-zone predominance)
- 3. Hypoxaemia at rest (or in mild cases, with exertion)

Cotrimoxazole (Bactrim)

PLUS

Prednisone if severe disease $(pO_2 < 70 \text{ mmHg, or alveolar-arterial gradient} > 35)$

• Consider empiric treatment if the above criteria are met:



Basic work-up of patients with SARI

- Chest X-ray
- Blood cultures
- If productive of sputum: sputum MCS
- Samples for COVID-2019 testing
- If available (private sector > public sector)
 - Nasopharyngeal and oropharyngeal swabs for respiratory viruses and atypical pathogens
 - Urine Legionella antigen
- If PCP suspected:
 - Serum beta-D-glucan
 - Sputum sample / bronchoalveolar lavage (not always possible) for PCP




Supportive management of SARI

- Oxygen if required (titrate to SpO₂ ≥ 90%, or 92-95% in pregnant patients)
- Ventilatory support if required
 - If ARDS develops, consider neuromuscular prone position, and use lungprotective ventilation:
 - Low tidal volumes of 6 mL/kg or less
 - Low plateau airway pressure of 30 cm H₂O or less
 - Moderate-high PEEP levels to recruit lung
- Restrictive fluid management (unless shock or acute kidney injury)
- ... and other standard supportive measures in critically ill patients (consider thromboprophylaxis, neuromuscular blockade, prone position, and lung protective ventilation.)




Co-ordinating a public health response

Phases of a pandemic – and appropriate responses





IMS Team





Thank You

Reduce your risk of coronavirus infection:



Clean hands with soap and water or alcohol-based hand rub

Cover nose and mouth when coughing and sneezing with tissue or flexed elbow






Avoid close contact with anyone with cold or flu-like symptoms

Thoroughly cook meat and eggs





Avoid unprotected contact with live wild or farm animals



